EMEA-001186-PIP01-11-M03
Key facts
| Invented name |
Iclusig
|
| Active substance |
Ponatinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0122/2022
|
| PIP number |
EMEA-001186-PIP01-11-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Incyte Biosciences Distribution B.V.
E-mail: globalmedinfo@incyte.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|